Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs

JAMA Health Forum 2026 Open access

Read full text
Authors: Thomas J. Hwang, Ariadna Tibau, Aaron S Kesselheim, Kerstin Noelle Vokinger
DOI: 10.1001/jamahealthforum.2026.0509
Cited by: 1
References: 2

Abstract

This cross-sectional study explores expenditures, negotiated pricing, and potential additional savings for top-selling cancer products in Medicare Part B and Part D.

Fields of Study & Subjects

Healthcare Policy and Management Medication Adherence and Compliance Economic and Financial Impacts of Cancer

Publication details

Journal / source
JAMA Health Forum
Publisher
American Medical Association (AMA)
Volume
7
Issue
5
Pages
e260509–e260509
Publication date
1 May 2026
Language
EN